Results 261 to 270 of about 488,286 (382)

Prescriptions of Essentially Placebo Treatments Among General Practitioners in 21 Countries.

JAMA Netw Open
Wolters F, Peerdeman K, Gussekloo J, Adler L, Asenova R, Kánská PB, Collins C, Dumitra GG, Howick J, Peštic SK, Kurpas D, Lazic V, Lingner H, Mallen CD, Missiou A, Peremans L, Petrazzuoli F, Pilv-Toom L, Poortvliet RKE, Thulesius HO, Torzsa P, Tsopra R, Tkachenko V, Viegas R, Evers AWM, Streit S.   +25 more
europepmc   +1 more source

Conditioned open-label placebos to facilitate opioid reduction in patients with chronic non-cancer pain: study protocol of a randomised controlled trial. [PDF]

BMJ Open
Carratta K, Bodonyi K, Frey Nascimento A, Friis D, von Känel R, Bircher L, Koechlin H, Bernstein M, Streitberger K, Arnet I, Roth AJ, Ronel J, Olliges E, Locher C.   +13 more
europepmc   +1 more source

Some Ethical Reflections on AIDS [PDF]

, 1988
LaChat, Michael
core   +1 more source

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment

British Journal of Clinical Pharmacology, EarlyView.
Aims Crisugabalin is a novel calcium channel α2δ subunit ligand and a highly selective oral gamma‐aminobutyric acid (GABA) analogue developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and postherpetic neuralgia (PHN). This study investigated pharmacokinetic properties and safety of crisugabalin in subjects with renal impairment ...
Shibeilei Lin, Ye Wang, Chao Hu, Yanhuan Feng, Xi Tang, Ping Fu, Jia Miao   +6 more
wiley   +1 more source

Acute and prolonged toxicity assessment of Cannabis sativa extract in rodents and lagomorphs. [PDF]

Toxicol Rep
Costa AC, Gasparotto A, Garcia AAK, Pereira CAC, Lourenço ELB, Joaquim HPG.   +5 more
europepmc   +1 more source

Paternalism, Placebos, and Informed Consent in Psychotherapy

, 2016
C. Blease, M. Trachsel, M. Holtforth
semanticscholar   +1 more source

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In‐Jin Jang, Sang‐Ku Yoo, Kyung‐Sang Yu   +5 more
wiley   +1 more source

A systematic review and meta analysis of open label placebo effects in chronic musculoskeletal pain. [PDF]

Sci Rep
Borg F, Gedin F, Franzén E, Grooten WJA.   +3 more
europepmc   +1 more source

Double-blind, randomized comparison of 24 weeks of norfloxacin and 12 weeks of norfloxacin followed by 12 weeks of placebo in the therapy of complicated urinary tract infection

, 1988
G. J. Sheehan, G. K. M. Harding, D A Haase, Margaret Thomson, B Urias, Jim Kennedy, D. J. Hoban, Allan Ronald   +7 more
openalex   +1 more source

Research Interviews in Historical Practice

Berichte zur Wissenschaftsgeschichte, EarlyView.
A key difference between collecting life stories and doing research interviews is the role of the interviewer. While training in oral history may focus on using standard scripts to take a life story, research interviews are motivated by specific questions that arise from particular historical projects and are often not primarily focused on the ...
Lara Keuck, Soraya de Chadarevian
wiley   +1 more source